


Rutgers Cancer Institute of New Jersey



Clinical Trials Connection

A Cancer Resource for Healthcare Professionals November 2015

[Resources for Physicians](#)

 [Send to a Colleague](#)

 [Join Our Mailing List](#)



Anna Ferrari, MD

is the director of the Genitourinary Program at Rutgers Cancer Institute of New Jersey, and a professor of medicine at Rutgers Robert Wood Johnson Medical School. Dr. Ferrari is involved in the development of protocols that investigate novel agents in the treatment of genitourinary cancers.

Contact Dr. Ferrari:
af661@cinj.rutgers.edu
732-235-8599

Clinical Trial Spotlight

Phase I Trial of ONC201 in Patients with Advanced Solid Tumors

The purpose of this study is to establish safe dosing levels for

Genitourinary Clinical Trials

[View printable version](#)

ECOG E2810: Phase III Adjuvant Pazopanib in Metastatic Renal Cell Carcinoma after Metastatectomy

The study aims to:

- Evaluate disease-free survival with pazopanib as compared to placebo, defined as the time from randomization to the development of recurrent disease, second primary cancer (other than localized breast, localized prostate, or non-melanoma skin cancer) or death from any cause for patients with metastatic RCC with no evidence of disease following metastatectomy.

[Learn more about this trial](#)

A Phase III Randomized Study of DCVAC/PCa versus Placebo in Metastatic CRPC Undergoing First Line Chemotherapy

The study aims to:

- Show superiority of treatment with DCVAC/PCa in addition to Standard of Care Chemotherapy over placebo in addition to Standard of Care Chemotherapy in men with mCRPC as measured by OS.
- Assess safety, time to tumor progression, time to prostate-specific antigen progression, progression free survival, occurrence of skeletal related events (SRE), proportion of patients requiring second line treatment introduction.

[Learn more about this trial](#)

Salvage Therapeutic Radiation with Enzalutamide and ADT in Men with Recurrent Prostate Cancer (STREAM)

The study aims to:

an agent known as ONC201, which research has shown may be capable of turning off proteins that maintain tumor growth and may help kill cancer cells while sparing normal ones. Those with solid tumors including glioblastoma are eligible to participate, although other criteria must also be met.

[Learn more](#)

Other Available Trials

[Breast](#)

[Gastrointestinal/
Hepatobiliary](#)

[Gynecologic](#)

[Hematologic](#)

[Melanoma](#)

[Pediatric](#)

[Phase I](#)

[Prostate](#)

[Thoracic](#)

The study aims to:

- Describe the 2 year progression-free survival in men with recurrent PSA-only disease after prostatectomy receiving combined enzalutamide and standard androgen-deprivation therapy with salvage radiation therapy and who have had testosterone recovery to greater than 100 at 24 months.
- Determine the proportion of men at 1, 2 and 3 years with a PSA of less than 0.1 ng/mL and testosterone recovery to greater than 100.
- Describe the 3 year progression-free survival in men receiving combined enzalutamide and standard androgen-deprivation therapy with salvage radiation therapy and who have had testosterone recovery to greater than 100.
- Describe the biochemical (PSA) progression free survival over time.

[Learn more about this trial](#)

A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination with PANVAC Versus BCG Given Alone in Adults with High Grade Non-Muscle Invasive Bladder Cancer

The study aims to:

- Determine if there is an improvement in disease-free survival (DFS) with BCG + PANVAC compared with BCG alone in a phase II study in non-muscle invasive high-grade urothelial carcinoma of the bladder who have failed to respond to intravesical BCG.

[Learn more about this trial](#)

MK-3475 Plus Bevacizumab for Metastatic

Renal Cancer

The study aims to:

- (Phase Ib Dose Escalation Cohort:) Establish the maximum tested safe dose of study drug pembrolizumab (MK-3475) and bevacizumab in combination for subjects with metastatic clear cell renal carcinoma after failure of at least one systemic therapy for metastatic disease.
- (Phase II Study:) Determine the activity of combination of pembrolizumab and bevacizumab in first line therapy for subjects with treatment naïve metastatic clear cell RCC as assessed by response rates (complete or partial response) (RR) based on RECIST.

[Learn more about this trial](#)



A Comprehensive Cancer
Center Designated by the
National Cancer Institute

A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial

The study aims to:

- Determine if treatment with supraphysiologic testosterone will improve radiographic progression free survival compared to enzalutamide in asymptomatic men with evidence of progressive metastatic CRPC post-treatment with abiraterone.
- Investigate the safety of cyclical parenteral testosterone in asymptomatic men with recurrent castrate resistant prostate cancer.

[Learn more about this trial](#)

Pembrolizumab in Subjects with Metastatic Urothelial Cancer Ineligible for Cisplatin

The study aims to:

- Evaluate anti-tumor activity of pembrolizumab (MK-3475) as 1L therapy in subjects with advanced/unresectable or metastatic urothelial cancer who are ineligible for cisplatin-based therapy and whose tumors express PD-L1 protein by IHC based on RECIST 1.1 assessed by independent radiology review.

[Learn more about this trial](#)



As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey offers patients access to treatment options not available at other institutions within the state. The Cancer Institute currently enrolls approximately 17 percent of all new adult cancer patients and approximately 70 percent of all pediatric cancer patients onto a clinical trial. Enrollment in these studies nationwide is fewer than five percent of all adult cancer patients.

[Learn more](#)

[Forward this email](#)